Firethorn Wealth Partners LLC Makes New $204,000 Investment in HCA Healthcare, Inc. $HCA

Firethorn Wealth Partners LLC purchased a new position in shares of HCA Healthcare, Inc. (NYSE:HCA) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 533 shares of the company’s stock, valued at approximately $204,000.

A number of other large investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its position in HCA Healthcare by 83.4% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,399,372 shares of the company’s stock worth $829,104,000 after acquiring an additional 1,091,416 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in HCA Healthcare by 49.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,781,459 shares of the company’s stock worth $615,583,000 after acquiring an additional 587,036 shares during the last quarter. Nuveen LLC acquired a new stake in shares of HCA Healthcare in the 1st quarter valued at approximately $569,217,000. Pacer Advisors Inc. boosted its holdings in shares of HCA Healthcare by 6,237.9% in the 1st quarter. Pacer Advisors Inc. now owns 1,350,933 shares of the company’s stock valued at $466,815,000 after buying an additional 1,329,618 shares during the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in shares of HCA Healthcare by 0.8% in the 1st quarter. Principal Financial Group Inc. now owns 880,663 shares of the company’s stock valued at $304,313,000 after buying an additional 6,888 shares during the last quarter. Institutional investors and hedge funds own 62.73% of the company’s stock.

HCA Healthcare Price Performance

HCA stock opened at $429.52 on Friday. The stock has a market capitalization of $100.50 billion, a price-to-earnings ratio of 18.05, a PEG ratio of 1.35 and a beta of 1.40. The business’s fifty day moving average price is $397.53 and its two-hundred day moving average price is $372.65. HCA Healthcare, Inc. has a fifty-two week low of $289.98 and a fifty-two week high of $432.36.

HCA Healthcare (NYSE:HCA) last posted its quarterly earnings data on Friday, July 25th. The company reported $6.84 earnings per share for the quarter, topping the consensus estimate of $6.20 by $0.64. The firm had revenue of $18.61 billion for the quarter, compared to analysts’ expectations of $18.49 billion. HCA Healthcare had a negative return on equity of 7,363.11% and a net margin of 8.21%.The company’s quarterly revenue was up 6.4% compared to the same quarter last year. During the same quarter last year, the business earned $5.50 EPS. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. Research analysts expect that HCA Healthcare, Inc. will post 24.98 EPS for the current year.

HCA Healthcare Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Tuesday, September 16th were given a $0.72 dividend. The ex-dividend date was Tuesday, September 16th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.7%. HCA Healthcare’s dividend payout ratio (DPR) is presently 12.11%.

Insider Activity at HCA Healthcare

In related news, EVP Michael S. Cuffe sold 3,836 shares of the firm’s stock in a transaction on Monday, September 8th. The stock was sold at an average price of $418.84, for a total value of $1,606,670.24. Following the transaction, the executive vice president owned 31,503 shares in the company, valued at approximately $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.30% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on HCA shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $444.00 price objective on shares of HCA Healthcare in a report on Tuesday, August 26th. Robert W. Baird increased their price objective on HCA Healthcare from $380.00 to $423.00 and gave the company a “neutral” rating in a report on Thursday, August 14th. Wolfe Research downgraded HCA Healthcare from an “outperform” rating to a “peer perform” rating in a report on Monday, July 28th. Wall Street Zen raised HCA Healthcare from a “hold” rating to a “buy” rating in a report on Saturday, July 5th. Finally, Royal Bank Of Canada cut their price target on HCA Healthcare from $404.00 to $401.00 and set an “outperform” rating for the company in a report on Monday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $407.75.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.